Top

Irish Journal of Medical Science (1971 -)

Published in:

21-07-2023 | Alzheimer's Disease | Review Article

Identification of common core ion channel genes in epilepsy and Alzheimer’s disease

Authors: Ting Tang, Xiang Li, Erhan Yu, Man Li, Xiaodong Pan

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2024

Abstract

Background

Although available literature indicates that the incidence of dementia in the epilepsy population and the risk of seizures in the Alzheimer’s disease (AD) population are high, the specific genetic risk factors and the interaction mechanism are unclear, rendering rational genetic interpretation rather challenging.

Aims

Our work aims to identify the common core ion channel genes in epilepsy and AD.

Methods

In this study, we first integrated gene expression omnibus datasets (GSE48350 and GSE6834) on AD and epilepsy to identify differentially expressed genes (DEGs), performing Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DEGs. The related protein–protein interaction (PPI) network was constructed for DEGs, and the hub gene was evaluated.

Results

A total of 2800 and 35 genes were identified in GSE48350 and GSE6834, and 12 DEGs were significantly differentially expressed between the datasets. KEGG pathway analysis showed that DEGs were primarily enriched in glutamatergic synapse and dopaminergic synapse pathways. SCN2A, GRIA1, and KCNJ9 were the hub genes with high connectivity.

Conclusions

The findings suggest that the three genes, SCN2A, GRIA1, and KCNJ9, may serve as potential targets for treating AD comorbid with epilepsy.

Maloney EM, Chaila E, O’Reilly ÉJ, Costello DJ (2020) Incidence of first seizures, epilepsy, and seizure mimics in a geographically defined area. Neurology 95:e576–e590. https://doi.org/10.1212/wnl.0000000000009980CrossRefPubMed

Qi S, Yin P, Zhang H et al (2021) Prevalence of dementia in China in 2015: a nationwide community-based study. Frontiers in public health 9:733314. https://doi.org/10.3389/fpubh.2021.733314

Hampel H, Hardy J, Blennow K et al (2021) The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry 26:5481–5503. https://doi.org/10.1038/s41380-021-01249-0[pii]CrossRefPubMedPubMedCentral

Wang S, Colonna M (2019) Microglia in Alzheimer’s disease: a target for immunotherapy. J Leukoc Biol 106:219–227. https://doi.org/10.1002/JLB.MR0818-319RCrossRefPubMed

Hall AM, Moore RY, Becker JT et al (2008) Basal forebrain atrophy is a presymptomatic marker for Alzheimer’s disease. Alzheimers Dement 4:271–279. https://doi.org/10.1016/j.jalz.2008.04.005CrossRefPubMed

Carter TL, Rissman RA, Mishizen-Eberz AJ et al (2004) Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer’s disease patients according to Braak stage. Exp Neurol 187:299–309. https://doi.org/10.1016/j.expneurol.2003.12.010CrossRefPubMed

Mrabet H, Mrabet A, Mansour M (2007) Epidemiological and medical aspects of epilepsy in the elderly. Tunis Med 85:67PubMed

Vossel KA, Tartaglia MC, Miller BL et al (2017) Epileptic activity in Alzheimer’s disease: causes and clinical relevance. Lancet Neurol 16:311–322. https://doi.org/10.1016/S1474-4422(17)30044-3CrossRefPubMedPubMedCentral

van Vliet EA, Marchi N (2022) Neurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging. Epilepsia. https://doi.org/10.1111/epi.17210CrossRefPubMedPubMedCentral

10.

Johannesen KM, Nikanorova N, Marjanovic D et al (2020) Utility of genetic testing for therapeutic decision-making in adults with epilepsy. Epilepsia 61:1234–1239. https://doi.org/10.1111/epi.16533CrossRefPubMed

11.

Kang JQ, Shen W, Zhou C et al (2015) The human epilepsy mutation GABRG2(Q390X) causes chronic subunit accumulation and neurodegeneration. Nat Neurosci 18:988–996. https://doi.org/10.1038/nn.4024CrossRefPubMedPubMedCentral

12.

DiFrancesco JC, Tremolizzo L, Polonia V et al (2017) Adult-onset epilepsy in presymptomatic Alzheimer’s disease: a retrospective study. J Alzheimers Dis 60:1267–1274. https://doi.org/10.3233/JAD-170392CrossRefPubMed

13.

Kawakami O, Koike Y, Ando T et al (2018) Incidence of dementia in patients with adult-onset epilepsy of unknown causes. J Neurol Sci 395:71–76. https://doi.org/10.1016/j.jns.2018.09.010CrossRefPubMed

14.

Beghi E, Beghi M (2020) Epilepsy, antiepileptic drugs and dementia. Curr Opin Neurol 33:191–197. https://doi.org/10.1097/WCO.0000000000000802CrossRefPubMed

15.

Busche MA, Chen X, Henning HA et al (2012) Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 109:8740–8745. https://doi.org/10.1073/pnas.1206171109CrossRefPubMedPubMedCentral

16.

Pooler AM, Phillips EC, Lau DH et al (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14:389–394. https://doi.org/10.1038/embor.2013.15CrossRefPubMedPubMedCentral

17.

Gourmaud S, Shou H, Irwin DJ et al (2020) Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. Brain 143:191–209. https://doi.org/10.1093/brain/awz381CrossRefPubMed

18.

Dejakaisaya H, Kwan P, Jones NC (2021) Astrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer’s disease. Epilepsia 62:1485–1493. https://doi.org/10.1111/epi.16918CrossRefPubMed

19.

Menezes LFS, Sabiá Júnior EF, Tibery DV et al (2020) Epilepsy-related voltage-gated sodium channelopathies: a review. Front Pharmacol 11:1276. https://doi.org/10.3389/fphar.2020.01276CrossRefPubMedPubMedCentral

20.

Wang R, Reddy PH (2017) Role of glutamate and NMDA receptors in Alzheimer’s disease. J Alzheimers Dis 57:1041–1048. https://doi.org/10.3233/JAD-160763CrossRefPubMedPubMedCentral

21.

Nixon RA (2020) The aging lysosome: an essential catalyst for late-onset neurodegenerative diseases. Biochimica et biophysica acta Proteins and proteomics 1868:140443. https://doi.org/10.1016/j.bbapap.2020.140443

22.

Venegas C, Heneka MT (2019) Inflammasome-mediated innate immunity in Alzheimer’s disease. FASEB J 33:13075–13084. https://doi.org/10.1096/fj.201900439CrossRefPubMed

23.

Rana A, Musto AE (2018) The role of inflammation in the development of epilepsy. J Neuroinflammation 15:144. https://doi.org/10.1186/s12974-018-1192-7CrossRefPubMedPubMedCentral

24.

Dun C, Zhang Y, Yin J et al (2022) Bi-directional associations of epilepsy with dementia and Alzheimer’s disease: a systematic review and meta-analysis of longitudinal studies. Age Ageing 51. https://doi.org/10.1093/ageing/afac010

25.

Romoli M, Sen A, Parnetti L et al (2021) Amyloid-β: a potential link between epilepsy and cognitive decline. Nat Rev Neurol 17:469–485. https://doi.org/10.1038/s41582-021-00505-9CrossRefPubMed

26.

Liu J, Wang LN (2021) Treatment of epilepsy for people with Alzheimer’s disease. Cochrane Database Syst Rev 5:CD011922. https://doi.org/10.1002/14651858.CD011922.pub4

27.

Piccini A, Carta S, Tassi S et al (2008) ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci USA 105:8067–8072. https://doi.org/10.1073/pnas.0709684105CrossRefPubMedPubMedCentral

28.

O'Neill C, Cowburn RF, Bonkale WL et al (2001) Dysfunctional intracellular calcium homoeostasis: a central cause of neurodegeneration in Alzheimer’s disease. Biochem Soc Symp:177–194. https://doi.org/10.1042/bss0670177

29.

Gatz M, Reynolds CA, Fratiglioni L et al (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63:168–174. https://doi.org/10.1001/archpsyc.63.2.168CrossRefPubMed

30.

Bellenguez C, Charbonnier C, Grenier-Boley B et al (2017) Contribution to Alzheimer’s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging 59:220 e221-220 e229. https://doi.org/10.1016/j.neurobiolaging.2017.07.001CrossRef

31.

Kim M, Bezprozvanny I (2021) Conformational models of APP processing by gamma secretase based on analysis of pathogenic mutations. Int J Mol Sci 22. https://doi.org/10.3390/ijms222413600

32.

Zhao Y, Kiss T, DelFavero J et al (2020) CD82-TRPM7-Numb signaling mediates age-related cognitive impairment. Geroscience 42:595–611. https://doi.org/10.1007/10.1007/s11357-020-00166-4CrossRefPubMedPubMedCentral

33.

Lu R, Wang J, Tao R et al (2018) Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer’s disease and mild cognitive impairment. Mol Psychiatry 23:767–776. https://doi.org/10.1038/mp.2017.136CrossRefPubMed

34.

Lu J, Zhou W, Dou F et al (2021) TRPV1 sustains microglial metabolic reprogramming in Alzheimer’s disease. EMBO Rep 22:e52013. https://doi.org/10.15252/embr.202052013

35.

Paumier A, Boisseau S, Jacquier-Sarlin M et al (2022) Astrocyte-neuron interplay is critical for Alzheimer’s disease pathogenesis and is rescued by TRPA1 channel blockade. Brain 145:388–405. https://doi.org/10.1093/brain/awab281CrossRefPubMed

36.

Hefter D, Ludewig S, Draguhn A, Korte M (2020) Amyloid, APP, and electrical activity of the brain. Neuroscientist 26:231–251. https://doi.org/10.1177/1073858419882619CrossRefPubMed

37.

Shu HF, Yu SX, Zhang CQ et al (2013) Expression of TRPV1 in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. Brain Dev 35:252–260. https://doi.org/10.1016/j.braindev.2012.04.007CrossRefPubMed

38.

Günaydın C, Arslan G, Bilge SS (2020) Proconvulsant effect of trans-cinnamaldehyde in pentylenetetrazole-induced kindling model of epilepsy: the role of TRPA1 channels. Neurosci Lett 721:134823. https://doi.org/10.1016/j.neulet.2020.134823

39.

Griciuc A, Patel S, Federico AN et al (2019) TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron 103:820-835 e827. https://doi.org/10.1016/j.neuron.2019.06.010CrossRefPubMedPubMedCentral

40.

Deming Y, Filipello F, Cignarella F et al (2019) The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk. Sci Transl Med 11. https://doi.org/10.1126/scitranslmed.aau2291

41.

Sala Frigerio C, Wolfs L, Fattorelli N et al (2019) The major risk factors for Alzheimer’s disease: age, sex, and genes modulate the microglia response to Aβ plaques. Cell Rep 27:1293-1306 e1296. https://doi.org/10.1016/j.celrep.2019.03.099CrossRefPubMed

42.

Frank MG, Weber MD, Fonken LK et al (2016) The redox state of the alarmin HMGB1 is a pivotal factor in neuroinflammatory and microglial priming: a role for the NLRP3 inflammasome. Brain Behav Immun 55:215–224. https://doi.org/10.1016/j.bbi.2015.10.009CrossRefPubMed

43.

Fujita K, Motoki K, Tagawa K et al (2016) HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer’s disease. Sci Rep 6:31895. https://doi.org/10.1038/srep31895CrossRefPubMedPubMedCentral

44.

Choy M, Dubé CM, Patterson K et al (2014) A novel, noninvasive, predictive epilepsy biomarker with clinical potential. J Neurosci 34:8672–8684. https://doi.org/10.1523/JNEUROSCI.4806-13.2014CrossRefPubMedPubMedCentral

45.

Wang XD, Liu S, Lu H et al (2021) Analysis of shared genetic regulatory networks for Alzheimer’s disease and epilepsy. Biomed Res Int 2021:6692974. https://doi.org/10.1155/2021/6692974CrossRefPubMedPubMedCentral

46.

Nabavi S, Fox R, Proulx CD et al (2014) Engineering a memory with LTD and LTP. Nature 511:348–352. https://doi.org/10.1038/nature13294CrossRefPubMedPubMedCentral

47.

Kang JQ (2021) Epileptic mechanisms shared by Alzheimer’s disease: viewed via the unique lens of genetic epilepsy. Int J Mol Sci 22. https://doi.org/10.3390/ijms22137133

48.

Gourmaud S, Stewart DA, Irwin DJ et al (2022) The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer’s disease. Brain : a journal of neurology 145:324–339. https://doi.org/10.1093/brain/awab268CrossRefPubMed

49.

Huang K, Fingar DC (2014) Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol 36:79–90. https://doi.org/10.1016/j.semcdb.2014.09.011CrossRefPubMed

50.

Sanders SJ, Campbell AJ, Cottrell JR et al (2018) Progress in understanding and treating SCN2A-mediated disorders. Trends Neurosci 41:442–456. https://doi.org/10.1016/j.tins.2018.03.011CrossRefPubMedPubMedCentral

51.

Hedrich UBS, Lauxmann S, Lerche H (2019) SCN2A channelopathies: mechanisms and models. Epilepsia 60(Suppl 3):S68–S76. https://doi.org/10.1111/epi.14731CrossRefPubMed

52.

Middleton SJ, Kneller EM, Chen S et al (2018) Altered hippocampal replay is associated with memory impairment in mice heterozygous for the Scn2a gene. Nat Neurosci 21:996–1003. https://doi.org/10.1038/s41593-018-0163-8CrossRefPubMedPubMedCentral

53.

Spratt PWE, Ben-Shalom R, Keeshen CM et al (2019) The autism-associated gene Scn2a contributes to dendritic excitability and synaptic function in the prefrontal cortex. Neuron 103:673-685 e675. https://doi.org/10.1016/j.neuron.2019.05.037CrossRefPubMedPubMedCentral

54.

Harutyunyan A, Jones NC, Kwan P, Anderson A (2022) Network preservation analysis reveals dysregulated synaptic modules and regulatory hubs shared between Alzheimer’s disease and temporal lobe epilepsy. Front Genet 13:821343. https://doi.org/10.3389/fgene.2022.821343

55.

Wolff M, Johannesen KM, Hedrich UBS et al (2017) Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain 140:1316–1336. https://doi.org/10.1093/brain/awx054CrossRefPubMed

56.

Heinzen EL, Yoon W, Weale ME et al (2007) Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer’s disease. Genome Biol 8:R32. https://doi.org/10.1186/gb-2007-8-3-r32CrossRefPubMedPubMedCentral

57.

Sommer B, Keinänen K, Verdoorn TA et al (1990) Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249:1580–1585. https://doi.org/10.1126/science.1699275CrossRefPubMed

58.

Neuner SM, Wilmott LA, Hoffmann BR et al (2017) Hippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer’s disease mouse models. Behav Brain Res 322:288–298. https://doi.org/10.1016/j.bbr.2016.06.002CrossRefPubMed

59.

Kim JE, Lee DS, Park H et al (2021) Inhibition of AKT/GSK3β/CREB pathway improves the responsiveness to AMPA receptor antagonists by regulating GRIA1 surface expression in chronic epilepsy rats. Biomedicines 9. https://doi.org/10.3390/biomedicines9040425

60.

Hibino H, Inanobe A, Furutani K et al (2010) Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev 90:291–366. https://doi.org/10.1152/physrev.00021.2009CrossRefPubMed

61.

Kempermann G, Chesler EJ, Lu L et al (2006) Natural variation and genetic covariance in adult hippocampal neurogenesis. Proc Natl Acad Sci USA 103:780–785. https://doi.org/10.1073/pnas.0510291103CrossRefPubMedPubMedCentral

62.

Heuser K, Nagelhus EA, Taubøll E et al (2010) Variants of the genes encoding AQP4 and Kir4.1 are associated with subgroups of patients with temporal lobe epilepsy. Epilepsy Res 88:55–64. https://doi.org/10.1016/j.eplepsyres.2009.09.023CrossRefPubMed

63.

Pravetoni M, Wickman K (2008) Behavioral characterization of mice lacking GIRK/Kir3 channel subunits. Genes Brain Behav 7:523–531. https://doi.org/10.1111/j.1601-183X.2008.00388.xCrossRefPubMed

64.

Kozell LB, Walter NA, Milner LC et al (2009) Mapping a barbiturate withdrawal locus to a 0.44 Mb interval and analysis of a novel null mutant identify a role for Kcnj9 (GIRK3) in withdrawal from pentobarbital, zolpidem, and ethanol. J Neurosci 29:11662–11673. https://doi.org/10.1523/JNEUROSCI.1413-09.2009CrossRefPubMedPubMedCentral

Title: Identification of common core ion channel genes in epilepsy and Alzheimer’s disease
Authors: Ting Tang
Xiang Li
Erhan Yu
Man Li
Xiaodong Pan
Publication date: 21-07-2023
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Epilepsy
Published in: Irish Journal of Medical Science (1971 -) / Issue 1/2024
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-023-03447-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Irish general practitioner (GP) perspectives on impact of direct access radiology on patient care in the community: results from a mixed-methods study

Prophylactic administration of metformin reduces gestational diabetes mellitus incidence in the high-risk populations: a meta-analysis

Comparison of inpatient outcomes in patients with Hepatitis B, Hepatitis C, and Hepatitis B and C co-infection with Cirrhosis

Reminiscence therapy relieves anxiety, depression and boosts spiritual well-being in both stroke patients and their spouse caregivers: a randomized, controlled study

Cardiorespiratory responses: Pilates compared to different walking speeds in healthy adults

Doublecortin-like kinase 3 (DCLK3) is associated with bad clinical outcome of patients with gastric cancer and regulates the ferroptosis and mitochondria function in vitro and in vivo

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage